Clinical trial
Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent…
NCT00005813 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00005813 |
|---|---|
| Title | Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme |
| Official title | A Phase I Trial of Intratumoral Bispecific Antibody and Activated Monocytes in Patients With Recurrent or Refractory Glioblastoma Multiforme |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Procedure |
| Interventions | bispecific antibody MDX447, lymphokine-activated killer cells, conventional surgery |
| Start date | Mar 1, 1997 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | May 20, 2003 |
| Last update posted | Oct 27, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: